Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Derek Maetzold, CEO of Castle Biosciences, sold shares of common stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On September 16, 2024, Derek J Maetzold, the President and CEO of Castle Biosciences, sold shares of the company's common stock.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2024.
- Maetzold sold 1,972 shares directly at a price of $30.972 per share.
- Additionally, shares held in various trusts for the benefit of his descendants and children were sold at the same price.
- These trusts include The Maetzold Descendants 2020 Trust (1,010 shares), Derek Maetzold 2020 Irrevocable Trust (948 shares), and several Maetzold 2018 Remainder Trusts (299 shares each for Emily Carol Kirk, Hannah Elizabeth Maetzold, John Derek Maetzold, and Peter Douglas Maetzold).
- Following these transactions, Maetzold directly owns 95,608 shares.
- He also indirectly owns shares through various trusts, including 78,656 shares via The Maetzold Descendants 2020 Trust, 67,683 shares via Derek Maetzold 2020 Irrevocable Trust, 7,360 shares via The Maetzold 2018 Remainder Trust FBO Emily Carol Kirk, 7,347 shares via The Maetzold 2018 Remainder Trust FBO Hannah Elizabeth Maetzold, 7,347 shares via The Maetzold 2018 Remainder Trust FBO John Derek Maetzold, 7,347 shares via The Maetzold 2018 Remainder Trust FBO Peter Douglas Maetzold, 122,866 shares via DJM Grantor Retained Annuity Trust No. 5, and 26,134 shares via DJM Grantor Retained Annuity Trust No. 6.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting the sale of shares by an insider. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.
Stakeholder Impact
- The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 05/24/2024 | Date of adoption of the Rule 10b5-1 plan. |
| 09/16/2024 | Date of the stock sale transaction. |
| 09/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.